UNSPSC 51372028: Levorphanol tartrate anhydrous

This classification denotes an opioid receptor agonist and opioid with the molecular formula C17H23NO.C4H6O6, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier WCB1I20F1K, chemically known as morphinan-3-ol, 17-methyl-, [r-(r*,r*)]-2,3-dihydroxybutanedioate (1:1) (salt), but more generally known as levorphanol tartrate anhydrous, which bears US NIH Compound Identifier 5464027.

European Medicines Agency schedules levorphanol tartrate anhydrous or its base in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB08490MIG. Most nations, for tariff purposes, schedule levorphanol tartrate anhydrous under HS 29334100. SMILES: CN1CC[C@]23CCCC[C@H]2[C@H]1CC4C3CC(CC4)O.[C@@H]([C@H](C(=O)O)O)(C(=O)O)O.

UNSPSC 51372028 Levorphanol tartrate anhydrous is a Commodity code that nominally names a specific opioid pharmaceutical, but recent state and local solicitations tagged under this code show minimal alignment with the narrow product scope — the opportunities instead cover broader pharmaceutical procurement including naloxone, generic multi-source drugs, and direct-to-manufacturer prescription programs. State and local governments soliciting under this code are primarily health departments, public health agencies, and multistate cooperative purchasing alliances that acquire pharmaceuticals, over-the-counter products, and opioid-related medications (including naloxone and drug deactivation systems) to support community health, substance-abuse response, and employee health-benefit programs. Issuing bodies include county health agencies, state health and human services departments, and cooperative purchasing consortia administering programs across multiple participating jurisdictions.

Recent activity spans Florida, Texas, and Minnesota, with the most visible recent opportunities including Seminole County, Florida's IFB60459723LAS (posted June 30, 2026, due July 26, 2023) seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through competitive bidding; the Texas Health and Human Services Commission's RFI HHS0017013 (posted April 3, 2026) gathering vendor capabilities for direct-to-manufacturer prescription fulfillment; and the Minnesota Multistate Cooperative Purchasing Alliance's RFP S1070000015802 (posted January 20, 2026, due March 26, 2026) establishing contracts for generic multi-source pharmaceuticals and OTC products distributed across state and local facilities in Minnesota and Oregon through authorized wholesalers. The code shows limited recent pharmaceutical-specific activity tied directly to levorphanol tartrate; pursuit should focus on the broader pharmaceutical-supply and health-benefit opportunities where state and local procurement offices are actively buying through this taxonomy.